RT Journal Article
T1 Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults.
A1 Jurado-Fasoli, Lucas
A1 Di, Xinyu
A1 Kohler, Isabelle
A1 Osuna-Prieto, Francisco J
A1 Hankemeier, Thomas
A1 Krekels, Elke
A1 Harms, Amy C
A1 Yang, Wei
A1 Garcia-Lario, Jose V
A1 Fernández-Veledo, Sonia
A1 Ruiz, Jonatan R
A1 Rensen, Patrick C N
A1 Martinez-Tellez, Borja
AB Omega-6 and omega-3 oxylipins are known to play a role in inflammation and cardiometabolic diseases in preclinical models. The associations between plasma levels of omega-6 and omega-3 polyunsaturated fatty acid-derived oxylipins and body composition and cardiometabolic risk factors in young adults were assessed. Body composition, brown adipose tissue, traditional serum cardiometabolic risk factors, inflammatory markers, and a panel of 83 oxylipins were analyzed in 133 young adults (age 22.1[SD 2.2] years, 67% women). Plasma levels of four omega-6 oxylipins (15-HeTrE, 5-HETE, 14,15-EpETrE, and the oxidative stress-derived 8,12-iso-iPF2α -VI) correlated positively with adiposity, prevalence of metabolic syndrome, fatty liver index, and homeostatic model assessment of insulin resistance index and lipid parameters. By contrast, the plasma levels of three omega-3 oxylipins (14,15-DiHETE, 17,18-DiHETE, and 19,20-DiHDPA) were negatively correlated with adiposity, prevalence of metabolic syndrome, fatty liver index, homeostatic model assessment of insulin resistance index, and lipid parameters. The panel of seven oxylipins predicted adiposity better than traditional inflammatory markers such as interferon gamma or tumor necrosis factor-alpha. Pathway analyses revealed that individuals with obesity had higher plasma levels of omega-6 and lower plasma levels of omega-3 oxylipins than normal-weight individuals. Plasma levels of seven omega-6 and omega-3 oxylipins may have utility as early markers of cardiometabolic risk in young adults.
YR 2021
FD 2021-12-12
LK http://hdl.handle.net/10668/22406
UL http://hdl.handle.net/10668/22406
LA en
DS RISalud
RD Apr 7, 2025